Why MMAD Testing Matters in Inhalation Product Development
GFN 2025: Changing Perceptions and Moving the Tobacco Harm Reduction Dialogue Forward
Our Chief Commercial Officer, Andy Mooney, recently attended the Global Forum on Nicotine (GFN) 2025 in Warsaw, where once again, science, policy and public health came together to advance the conversation on tobacco harm reduction.
All articles
Bringing a medical device to market isn’t just about innovation—it’s about precision, compliance,...
The Next Generation Nicotine Delivery (NGND) conference in Miami delivered an energetic and...
Introduction: Preparing for Regulatory Change in the Vape Industry
Recent Changes to CBD Regulations: What You Need to Know
The inaugural ATNF conference, held from 15–17 April 2025, brought together stakeholders across the...
As global economic dynamics shift, the reduced-risk nicotine industry, already contending with...
EVO NXT 2025 in Milan offered a refreshing departure from traditional large-scale expos. The event...
The UK heated tobacco market continues to evolve rapidly, with growing consumer interest and an...
If you have a specific question for one of our scientific or regulatory experts, get in touch with a member of our team today.
